COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00358371
Recruitment Status : Completed
First Posted : July 31, 2006
Last Update Posted : September 29, 2017
Information provided by (Responsible Party):

Brief Summary:
Primary objective:To study the absolute bioavailability, distribution and elimination parameters of flucloxacillin from two oral formulations of flucloxacillin in healthy male and/or female subjects.

Condition or disease Intervention/treatment Phase
Infections, Bacterial Drug: flucloxacillin 250 mg Drug: flucloxacillin 500 mg Phase 1

Detailed Description:
A mono-center, open, randomized, three-way, twelve-sequence, cross-over study to determine the extent of absorption (absolute bioavailability), rate of absorption and to further characterize distribution and elimination characteristics of a commercial 250 mg and a 500 mg capsule of flucloxacillin each given as a single oral dose vs. one 250 or 500 mg intravenous dose to 24 healthy male and/or female subjects in the fasting state

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Mono-center, Open, Randomized, Three-way, Twelve-sequence, Cross-over Study to Determine the Extent of Absorption (Absolute Bioavailability), Rate of Absorption and to Further Characterize Distribution and Elimination Characteristics of a Commercial 250 mg and a 500 mg Capsule of Flucloxacillin Each Given as a Single Oral Dose vs. One 250 or 500 mg Intravenous Dose to 24 Healthy Male and/or Female Subjects in the Fasting State
Actual Study Start Date : January 6, 2005
Actual Primary Completion Date : February 8, 2005
Actual Study Completion Date : February 8, 2005

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Subjects receiving flucloxacillin 250 mg
Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
Drug: flucloxacillin 250 mg
Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
Other Name: flucloxacillin

Experimental: Subjects receiving flucloxacillin 500 mg
Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
Drug: flucloxacillin 500 mg
Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose

Primary Outcome Measures :
  1. Absolute (Abs.) bioavailability, max. plasma conc., concentration-time curve (AUC) from 0 hto the last quantifiable conc., AUC from 0 h to infinity), timepoint of max. plasma conc., Halflife of drug elimination during the terminal phase [ Time Frame: Up to 60 Days ]

Secondary Outcome Measures :
  1. Elimination rate constant, total Clearance, Volume of distribution at steady state, Volume of distribution during the terminal phase, residual area [ Time Frame: Up to 60 Days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers,
  • Caucasians,
  • Body Mass Index (BMI) between 19 and 27 kg/m 2;
  • physically and mentally healthy as judged by means of a medical and standard lab examination;
  • non-smokers,
  • ex-smokers or moderate smoker.

Exclusion criteria:

  • medical history,
  • vital signs,
  • physical examination,laboratory tests (blood and/or urine) with evidence of clinically significant conditions;
  • 12-lead electrocardiogram (ECG) with clinically significant abnormality;acute infection within 2 weeks preceding 1st study drug administration;any medication on a regular basis (exception females: oral contraceptives) and/or tricyclic antidepressants, antacids, histamine H2-receptor antagonists, antibiotics,
  • non steroid anti-inflammatory drugs or anticoagulants within 8 weeks before the 1st study drug administration and/or no agreement to take any of those drugs including Over-the-counter (OTC) drugs until the end of the follow- up examination;
  • no agreement not to take any medication,including OTC medicine, antacids, or analgesics within 2 weeks before 1st drug administration until the end of the follow-up examination;special diet or loss of > 5 kg within last month from a weight reduction diet; regularly consume of large quantities of alcohol (> 20g/day) and/or beverages containing methylxanthines e.g. caffeine (> 0.5L/day altogether);
  • no agreement not to consume: - any beverages or foods containing alcohol 48 h prior to 1st study drug administration until end of the follow-up examination;
  • any grapefruit products 7 days prior 1st study drug administration until end of the follow-up examination,
  • any beverages or foods containing methylxanthines as well as fruit-juices and any foods containing poppy seed 48 h before 1st drug administration of either study period until last blood sample of the respective study period was collected,
  • not to consume chewing during confinement;
  • history of: - allergy to flucloxacillin,
  • B-lactams and/or related drugs,
  • known hypersensitivity against the inactive ingredients of the study medication,
  • hypersensitivity to multiple drugs,
  • allergic diseases,
  • acute hay fever,
  • previous history of flucloxacillin-associated jaundice/hepatic dysfunction,
  • alcohol or drug abuse,
  • epilepsy or other seizure,
  • psychiatric illness, e.g. latent or manifest depression schizophrenia, or neurosis,
  • respiratory diseases,
  • surgery of the gastrointestinal tract (except appendectomy),
  • kidney diseases,
  • bleeding/coagulation disorder or severe anaemia,
  • glucose-6-phosphate dehydrogenase deficiency and/or chronic treatment or chronic pathology;
  • metabolic disease;
  • evidence for disorder in the metabolism of pharmaceuticals or other foreign compounds; cardiovascular diseases e.g. hypertension, hypotension or bradycardia;
  • associated disease that would interfere with the clinical course of the trial;
  • major illness during 3 month before commencement of the screening period,
  • gastrointestinal diseases;
  • reported or positive results from test of drugs of abuse (amphetamines, opiates, barbiturate, methadone, cannabinoids, cocaine, benzodiazepines);
  • Positive test for: alcohol, Hepatitis-B-antigen or Hepatitis-C-antibody, HIV-antibody;blood donor or blood loss including plasmapheresis within the last 3 months before the 1st study drug administration;
  • intake of depot injectable solutions (including study medication) within 6 month before 1st study administration;
  • intake of enzyme-inducing and/or organotoxic drugs within 4 weeks before 1st study drug administration;for females only: positive results from pregnancy tests;does not use or not agree to use adequate contraceptive methods during the study;
  • lactating woman.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00358371

Layout table for location information
GSK Investigational Site
Greifswald, Mecklenburg-Vorpommern, Germany, 17487
Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline Identifier: NCT00358371    
Other Study ID Numbers: 103811
First Posted: July 31, 2006    Key Record Dates
Last Update Posted: September 29, 2017
Last Verified: September 2017
Keywords provided by GlaxoSmithKline:
bioavailability flucloxacillin
Additional relevant MeSH terms:
Layout table for MeSH terms
Bacterial Infections
Anti-Bacterial Agents
Anti-Infective Agents